RW-93

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

RW-93 is a drug which acts as a potent and selective sirtuin 2 (SIRT2) inhibitor. It inhibits SIRT2 with an IC 50 of 15.5 nM, and is highly selective over SIRT1, SIRT3 and SIRT5, however its activity has not been reported at SIRT4, SIRT6 or SIRT7. It represents a further development of FM358, which resulted from a lead-structure-based hybridization concept derived from SirReal2 and 24a. It was developed to assist with research into the role of SIRT2 in degenerative diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis.

RW-93 is a drug which acts as a potent and selective sirtuin 2 (SIRT2) inhibitor. It inhibits SIRT2 with an IC 50 of 15.5 nM, and is highly selective over SIRT1, SIRT3 and SIRT5, however its activity has not been reported at SIRT4, SIRT6 or SIRT7. It represents a further development of FM358, which resulted from a lead-structure-based hybridization concept derived from SirReal2 and 24a. It was developed to assist with research into the role of SIRT2 in degenerative diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1343201802 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.